Multiple Pharma Giants Fail Guangdong Drug Evaluations
This article was originally published in PharmAsia News
China Resources Sanjiu Medical & Pharmaceutical Co. Ltd., Chongqing Taiji Industry (Group) Co., Ltd., and Kangmei Pharmaceutical Co., Ltd. have failed the Guangdong government’s first quarter drug evaluations.
You may also be interested in...
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.